Robert W. Baird Boosts Exact Sciences (NASDAQ:EXAS) Price Target to $72.00

Exact Sciences (NASDAQ:EXAS - Get Free Report) had its price objective hoisted by Robert W. Baird from $69.00 to $72.00 in a report released on Friday,Benzinga reports. The brokerage presently has an "outperform" rating on the medical research company's stock. Robert W. Baird's price target would indicate a potential upside of 35.01% from the stock's previous close.

Several other research firms also recently weighed in on EXAS. Piper Sandler lowered their price target on shares of Exact Sciences from $75.00 to $70.00 and set an "overweight" rating for the company in a research note on Wednesday, February 26th. Mizuho started coverage on Exact Sciences in a research report on Thursday, April 10th. They issued an "outperform" rating and a $60.00 price objective on the stock. Royal Bank of Canada initiated coverage on shares of Exact Sciences in a research note on Thursday, March 13th. They issued a "sector perform" rating and a $52.00 price objective on the stock. William Blair reaffirmed an "outperform" rating on shares of Exact Sciences in a report on Thursday, February 20th. Finally, Bank of America reduced their target price on shares of Exact Sciences from $72.00 to $65.00 and set a "buy" rating on the stock in a report on Thursday, February 20th. Two analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $70.90.

Exact Sciences Trading Up 3.5 %

Shares of NASDAQ:EXAS traded up $1.78 during mid-day trading on Friday, reaching $53.33. 4,057,989 shares of the company's stock were exchanged, compared to its average volume of 2,643,092. Exact Sciences has a twelve month low of $39.97 and a twelve month high of $72.83. The company has a debt-to-equity ratio of 0.97, a quick ratio of 1.93 and a current ratio of 2.15. The firm has a market capitalization of $10.06 billion, a price-to-earnings ratio of -9.57 and a beta of 0.92. The business's fifty day moving average price is $45.02 and its 200-day moving average price is $53.20.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last posted its earnings results on Thursday, May 1st. The medical research company reported ($0.21) earnings per share for the quarter, topping analysts' consensus estimates of ($0.37) by $0.16. The company had revenue of $706.79 million for the quarter, compared to analyst estimates of $688.58 million. Exact Sciences had a negative net margin of 37.29% and a negative return on equity of 5.29%. The firm's revenue was up 10.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.60) EPS. On average, research analysts predict that Exact Sciences will post -0.58 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of EXAS. Tidal Investments LLC grew its holdings in shares of Exact Sciences by 172.2% during the 3rd quarter. Tidal Investments LLC now owns 34,275 shares of the medical research company's stock worth $2,335,000 after purchasing an additional 21,683 shares in the last quarter. Synovus Financial Corp acquired a new stake in shares of Exact Sciences in the third quarter valued at approximately $490,000. GAMMA Investing LLC increased its position in Exact Sciences by 29.1% in the fourth quarter. GAMMA Investing LLC now owns 3,674 shares of the medical research company's stock worth $206,000 after purchasing an additional 828 shares during the period. Modus Advisors LLC bought a new stake in shares of Exact Sciences during the 4th quarter valued at $43,000. Finally, Everence Capital Management Inc. acquired a new stake in Exact Sciences in the fourth quarter worth $356,000. Institutional investors and hedge funds own 88.82% of the company's stock.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.